HepGene
- Company typePrivate
- Founded2020
- Headquarters—
- Headcount1–10
- GTM typeB2B
- OfferingServices
HepGene firmographics
Firmographics- Name
- HepGene
- Legal name
- HepGene
- Website
- https://hepgene.bio
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
HepGene industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)
- akta.pro secondary industries
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Hepatology & Liver Disease (HLAKAEAB)
Keywords
HepGene business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Diagnostic Testing Services: As a liquid biopsy company developing diagnostic technology for MASLD, HepGene is expected to generate revenue through diagnostic testing services, likely as a laboratory-developed test (LDT) or FDA-cleared diagnostic product once their program reaches commercialization.
Go-to-market motion1 record
Marketing channels1 record
HepGene product offering
Product offeringCore offering
HepGene is developing a liquid biopsy diagnostic platform for early detection of metabolic dysfunction-associated steatotic liver disease (MASLD). The technology uses blood samples for non-invasive detection of metabolic liver disease at the earliest stages, when quality-of-life preservation interventions are most effective. The programs are currently under development and the company operates as a subsidiary of IVBH.
Product overview
HepGene is a liquid biopsy company offering early detection solutions for diseases affecting metabolic health, beginning with metabolic dysfunction-associated steatotic liver disease (MASLD). The company operates under the IVBH parent organization and focuses on quality-of-life preservation at the earliest disease stages. No specific named products, modules, or sub-brandings are detailed in the available source material.
Differentiator
Problem solved
Functional benefit
Products and services
- Liquid Biopsy MASLD Diagnostic
Companies that use HepGene
Customer profileSegments1 record
Ideal customer profiles1 record
HepGene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
HepGene partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
HepGene competitors and assessment
Company assessmentBroad incumbents
- Eurofins Scientific: Eurofins operates a large network of clinical and specialty diagnostics laboratories worldwide. Its specialty diagnostics arm routinely develops and commercializes biomarker assays, making it a relevant incumbent and potential commercial partner for HepGene.
- Laboratory Corporation of America (Labcorp): Labcorp is a major clinical lab network with established liver disease and metabolic testing services. It represents both a potential commercial distribution partner and a competitive incumbent in the MASLD diagnostic testing space.
- Quest Diagnostics: Quest Diagnostics is a large clinical reference laboratory offering extensive metabolic and liver-function panels, including specialized MASLD/MASH risk panels. As the likely commercial channel for any LDT-style launch, it is both a potential partner and competitive incumbent.
- Sonic Healthcare: Sonic Healthcare operates clinical laboratories across multiple geographies offering liver and metabolic testing panels. Its global scale makes it a relevant comparator for how specialized liver diagnostic tests reach market via reference lab channels.
Others
- Bio-Techne: Bio-Techne supplies proteins, antibodies, and biomarker assay reagents used by diagnostic developers. While not a direct competitor, it represents the reagent and assay-enabling ecosystem that HepGene's liquid biopsy platform depends on for development and scale-up.
Regional players
- Resonance Health: Resonance Health provides FerriScan and LiverMultiScan-adjacent MRI-based liver iron and fat quantification, primarily commercialized in Australia/Europe and via clinical trial partnerships. It is a relevant regional non-invasive liver diagnostic comparable.
Direct peers
- Genfit: Genfit develops diagnostics and therapeutics for NASH/MASLD, including biomarker programs historically partnered with major lab companies. Its deep domain focus on MASLD overlaps directly with HepGene's indication and biomarker thesis.
- Echosens: Echosens manufactures FibroScan, the leading non-invasive point-of-care device for liver fibrosis and steatosis assessment. It is the most established non-invasive alternative to liver biopsy in MASLD/MASH, making it the closest direct competitor to HepGene's liquid biopsy approach.
- Perspectum: Perspectum offers LiverMultiScan, an MRI-based quantitative liver assessment used in MASLD/MASH clinical trials and practice. As another non-invasive, non-biopsy diagnostic for metabolic liver disease, it competes head-to-head for the same clinical workflow HepGene targets.
Emerging players
- SomaLogic (now part of Standard BioTools): SomaLogic operates a large-scale proteomics platform that has been applied to MASLD biomarker discovery and risk stratification. As an emerging proteomic biomarker competitor, it is highly relevant to HepGene's blood-based biomarker thesis for metabolic liver disease.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
HepGene social profiles
Digital presenceHepGene financial estimates
Financial estimateRevenue estimate
Valuation estimate
HepGene leadership team
Management profileNumber of profiles
HepGene funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HepGene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HepGene
What does HepGene do?
HepGene is developing a liquid biopsy diagnostic platform for early detection of metabolic dysfunction-associated steatotic liver disease (MASLD). The technology uses blood samples for non-invasive detection of metabolic liver disease at the earliest stages, when quality-of-life preservation interventions are most effective. The programs are currently under development and the company operates as a subsidiary of IVBH.
Is HepGene a public or private company?
HepGene is a private company. It is classified as corporate owned and is currently operating.
When was HepGene founded?
HepGene was founded in 2020. It employs 1 to 10 people.
How does HepGene make money?
One revenue line is on record: diagnostic Testing Services.
Who are HepGene's main competitors?
Broad incumbents on record are Eurofins Scientific, Laboratory Corporation of America (Labcorp), Quest Diagnostics and Sonic Healthcare. Bio-Techne is listed as an others. Resonance Health is listed as a regional player. Direct peers are Genfit, Echosens and Perspectum. SomaLogic (now part of Standard BioTools) is listed as an emerging player.
Does HepGene have an API?
No public API is recorded for HepGene.
What industry is HepGene in?
HepGene's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 325413 and its SIC code is 2835.